Evidence map›Paper›PMID 36997926›Full record

ArticleBMC cancer2023

CD248 promotes migration and metastasis of osteosarcoma through ITGB1-mediated FAK-paxillin pathway activation.

Shiqi Lu, Tong Lu, Jiayu Zhang, Lunbiao Gan, Xinjie Wu, Donghui Han, Keying Zhang, Chao Xu, Shaojie Liu, Weijun Qin and 2 more

Open access · goldAbstract read
In one paragraph

Article in BMC cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Shiqi Lu *Xi'an Key Laboratory of Stem Cell and Regenerative Medicine, Institute of Medical Research, Northwestern Polytechnical University, 710072, Xi'an, Shaanxi, China.
Tong Lu *Department of Urology, Xijing Hospital, Air Force Medical University, Xi'an, China.
Jiayu Zhang *Department of Urology, Xijing Hospital, Air Force Medical University, Xi'an, China.
Lunbiao GanXi'an Key Laboratory of Stem Cell and Regenerative Medicine, Institute of Medical Research, Northwestern Polytechnical University, 710072, Xi'an, Shaanxi, China.
Xinjie WuXi'an Key Laboratory of Stem Cell and Regenerative Medicine, Institute of Medical Research, Northwestern Polytechnical University, 710072, Xi'an, Shaanxi, China.
Donghui HanDepartment of Urology, Xijing Hospital, Air Force Medical University, Xi'an, China.
Keying ZhangDepartment of Urology, Xijing Hospital, Air Force Medical University, Xi'an, China.
Chao XuDepartment of Urology, Xijing Hospital, Air Force Medical University, Xi'an, China.
Shaojie LiuDepartment of Urology, Xijing Hospital, Air Force Medical University, Xi'an, China.
Weijun QinDepartment of Urology, Xijing Hospital, Air Force Medical University, Xi'an, China. qinwj@fmmu.edu.cn.
Fa YangDepartment of Urology, Xijing Hospital, Air Force Medical University, Xi'an, China. yangfa@fmmu.edu.cn.
Weihong WenXi'an Key Laboratory of Stem Cell and Regenerative Medicine, Institute of Medical Research, Northwestern Polytechnical University, 710072, Xi'an, Shaanxi, China. weihongwen@nwpu.edu.cn.
Xijing Hospital · CNNorthwestern Polytechnical University · CNAir Force Medical University · CN

Funding

Fundamental Research Funds for the Central Universities G2021KY05102Innovation Capability Support Program of Shaanxi 2020PT-021National Natural Science Foundation of China No. 82173204Natural Science Basic Research Program of Shaanxi 2022JZ-62
6 · The paper itself

Abstract

backgroundOsteosarcoma (OS) is the most common malignant bone tumor with a high incidence in children and adolescents. Frequent tumor metastasis and high postoperative recurrence are the most common challenges in OS. However, detailed mechanism is largely unknown.

methodsWe examined the expression of CD248 in OS tissue microarrays by immunohistochemistry (IHC) staining. We studied the biological function of CD248 in cell proliferation, invasion and migration of OS cells by CCK8 assay, transwell and wound healing assay. We also studied its function in the metastasis of OS in vivo. At last, we explored the potential mechanism how CD248 promotes OS metastasis by using RNA-seq, western blot, immunofluorescence staining and co-immunoprecipitation using CD248 knockdown OS cells.

resultsCD248 was highly expressed in OS tissues and its high expression was correlated with pulmonary metastasis of OS. Knockdown of CD248 in OS cells significantly inhibited cell migration, invasion and metastasis, while had no obvious effect on cell proliferation. Lung metastasis in nude mice was significantly inhibited when CD248 was knocked down. Mechanistically, we found that CD248 could promote the interaction between ITGB1 and extracellular matrix (ECM) proteins like CYR61 and FN, which activated the FAK-paxillin pathway to promote the formation of focal adhesion and metastasis of OS.

conclusionOur data showed that high CD248 expression is correlated with the metastatic potential of OS. CD248 may promote migration and metastasis through enhancing the interaction between ITGB1 and certain ECM proteins. Therefore, CD248 is a potential marker for diagnosis and effective target for the treatment of metastatic OS.

Indexed as

Bone NeoplasmsLung NeoplasmsOsteosarcomaAnimalsAntigens, CDAntigens, NeoplasmCell Line, TumorCell MovementCell ProliferationFocal Adhesion Kinase 1Gene Expression Regulation, NeoplasticIntegrin beta1MiceMice, NudePaxillinAntigens, CDAntigens, NeoplasmCD248 protein, mouseFocal Adhesion Kinase 1Integrin beta1PaxillinPtk2 protein, mouseEndosialin/CD248/TEM-1ITGB1MetastasisMigrationOsteosarcoma

Identifiers

PMID36997926
PMCPMC10061858
OpenAlexW4361273396

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.